- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04029077
Introduction of the Vapor Treatment in The Netherlands (NEVEL)
Introduction in the NEtherlands of the Vapor Treatment for Patients With Severe Emphysema: a New Lungvolume Reduction Treatment
Rationale: The bronchoscopic lung volume reduction treatment using vapor was found to be effective and the treatment has an acceptable safety profile. The results of this trial has led to the inclusion of this treatment in the COPD GOLD guidelines in 2019. In the Netherlands the treatment has not been performed so far but the treatment device has been made available to the UMCG hospital to perform emphysema treatments. Some of the patients refered to the UMCG could benefit from the Vapor treatment and therefore with this treatment we will be able to treat patients who have no other treatment options left.
Objective: The overall aim of this study is to gain experience with the Thermal Vapor treatment by investigating the safety and efficacy of the treatment.
Primary Objective:
The primary objective is to investigate the change in Lung function (measured by Forced Expiratory Volume in 1 second (FEV1)) between baseline and 6 months after the Thermal Vapor treatment.
Study designThis study will be a prospective observational, single center study. All patients that undergo the bronchoscopic lung volume reduction treatment using thermal Vapor will be asked if their data can be captured in the database.
Study population: Patients with severe COPD who undergo the Thermal Vapor treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: The STEP-UP trial investigated the bronchoscopic lung volume reduction treatment using vapor and showed that the treatment group significantly improved after 6 months compared to the control group in Lung function and quality of life. The authors also concluded that the treatment has an acceptable safety profile. The results of this trial has led to the inclusion of this treatment in the COPD GOLD guidelines in 2019. In the Netherlands the treatment has not been performed so far but the treatment device has been made available to the UMCG hospital to perform emphysema treatments. Yearly, approximately 600 severe emphysema patients are refered to the UMCG for a bronchoscopic treatment but only approximately 10% is suitable for a treatment with endobronchial valves or coils. Some of the other patients could benefit from the Vapor treatment and therefore with this treatment we will be able to treat patients who have no other treatment options left.
Objective: The overall aim of this study is to gain experience with the Thermal Vapor treatment by investigating the safety and efficacy of the treatment.
Primary Objective:
The primary objective is to investigate the change in Lung function (measured by Forced Expiratory Volume in 1 second (FEV1)) between baseline and 6 months after the Thermal Vapor treatment.
Secondary Objectives:
Safety
• A secondary objective is to investigate the safety of the Thermal Vapor treatment by recoding all the adverse events that occur between baseline and 1 year follow up after treatment.
Efficacy • A secondary objective is to investigate the change in Lung function, lung hyperinflation, quality of life, dyspnea, CT parameters and exercise capacity between baseline and 6 and 12 months follow up after treatment.
Longterm
• A secondary objective is to investigate the long term effect of the treatment in terms of change in Lung function, lung hyperinflation, quality of life and exercise capacity between baseline and up to 5 years follow up after treatment.
Study designThis study will be a prospective observational, single center study that will investigate the safety and efficacy of the InterVapor (Bronchoscopic Thermal Vapor Ablation System) that will be introduced in the Netherlands for the first time. All patients that undergo the bronchoscopic lung volume reduction treatment using thermal Vapor will be asked if their data can be captured in the database.
Study population: Patients with severe COPD who undergo the Thermal Vapor treatment.
Main study parameters: The primary objective is to investigate the change in Lung function which will be measured by Forced Expiratory Volume in 1 second (FEV1) between baseline and 6 months after the Thermal Vapor treatment.
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of COPD
- FEV1%pred <45% and FVC<70%pred,
- Severe lung hyperinflation: RV>175%pred and RV/TLC>55%
- Patients will have heterogeneous emphysema, as evidenced by high-resolution CT demonstrating a heterogeneity Index >1.2 in at least one segment to be treated.
- Nonsmoking for at least 6 months prior to entering the study
- Completed a pulmonary rehabilitation program within 6 months prior to treatment and/or regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 months prior to baseline testing.
- Read, understood and signed the Informed Consent form.
Exclusion Criteria:
- FEV1 < 15% predicted
- Inability to walk >140 meters in 6 minutes (6MWD) following optimized medical management
- Subject has a history of recurrent clinically significant respiratory infections, defined as 3 or more hospitalizations for respiratory infection during the year prior to enrolment.
- Highly diseased lower lobes (tissue to air ratio of <11%)
- Presence of single large bulla (defined as > 1/3 volume of lobe) or a paraseptal distribution of emphysema in the treated lobe
- Subject has severe pulmonary hypertension defined by right ventricular systolic pressure >45 mm Hg via echocardiogram.
- Subject has severe gas exchange abnormalities as defined by: PaCO2 >8.0 kPa and/or PaO2 < 6.0 kPa (on room air).
- Subject has an inability to tolerate bronchoscopy under conscious sedation or general anaesthesia.
- Subject is taking >5 mg prednisone (or equivalent dose of a similar steroid) daily.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Vapor group
Bronchoscopic lung volume reduction treatment using Vapor
|
NA: it is not an interventional study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lung function
Time Frame: Between baseline and 6 months follow up
|
Change in Forced Expiratory Volume in 1 second (FEV1)
|
Between baseline and 6 months follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety by number of adverse events
Time Frame: Between baseline and 1 year follow up
|
Number of all adverse events
|
Between baseline and 1 year follow up
|
Lung function
Time Frame: Between baseline and 1 year follow up
|
Change in Forced Expiratory Volume in 1 second
|
Between baseline and 1 year follow up
|
Hyperinflation
Time Frame: Between baseline and 6 months follow up
|
Change in Residual Volume
|
Between baseline and 6 months follow up
|
Hyperinflation
Time Frame: Between baseline and 1 year follow up
|
Change in Residual Volume
|
Between baseline and 1 year follow up
|
Quality of life measured by a questionnaire
Time Frame: Between baseline and 6 months follow up
|
Change in St. George's Respiratory Questionnaire (SGRQ) total score (range 0-100, highest indicated worsed quality of life)
|
Between baseline and 6 months follow up
|
Quality of life measured by a questionnaire
Time Frame: Between baseline and 1 year follow up
|
Change in St. George's Respiratory Questionnaire (SGRQ) total score (range 0-100, highest indicated worsed quality of life)
|
Between baseline and 1 year follow up
|
Exercise capacity
Time Frame: Between baseline and 6 months follow up
|
Change in 6-minute walk distance (6MWD)
|
Between baseline and 6 months follow up
|
Exercise capacity
Time Frame: Between baseline and 12 months follow up
|
Change in 6-minute walk distance (6MWD)
|
Between baseline and 12 months follow up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dirk-Jan Slebos, MD PhD, Univeristy Medical Center Groningen
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEVEL-study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emphysema or COPD
-
University of Massachusetts, WorcesterUMass Memorial HealthEnrolling by invitation
-
Pulmonx CorporationActive, not recruiting
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
University of Colorado, DenverNational Jewish HealthUnknownRespiratory Failure | COPD | COPD Exacerbation | Emphysema or COPD | COPD Exacerbation Acute | Ventilatory FailureUnited States
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonarySpain, Germany, Italy, Australia
-
Universität Duisburg-EssenRecruiting
-
Uptake Medical Technology, Inc.MedPass InternationalCompleted
-
Zoar EngelmanRecruiting
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)RecruitingEmphysema | COPD | Emphysema or COPDUnited States
Clinical Trials on NA: intervention is not part of the study
-
Rambam Health Care CampusUnknownHodgkin Lymphoma Treated With Mediastinal IrradiationIsrael
-
Biosplice Therapeutics, Inc.Completed
-
Kardium Inc.St. Paul's Hospital, CanadaCompletedAtrial FibrillationCanada
-
Shanghai Mental Health CenterCompletedSchizophrenia | Cognitive Dysfunction | Neuroimaging
-
University College, LondonUniversity of LeedsUnknownMultimorbidityUnited Kingdom
-
University College, LondonUniversity of Leeds; Medical Research Council; University of EdinburghUnknownDementiaUnited Kingdom
-
Oslo University HospitalNot yet recruitingSchizophrenia | Cognitive Impairment | Social Competence
-
University of EdinburghKeele UniversityActive, not recruiting
-
Massachusetts General HospitalAstellas Pharma IncCompletedOveractive BladderUnited States